BCSCDB: Biomarkers of Cancer Stem Cells Database
Number of entries related to PC9 cell line is 113
| GENE | HGNC_ID | MARKER_TYPE | CANCER_TYPE | HISTOLOGICAL_TYPE | CELL_LINE | CSC_ENRICHMENT | METHOD | EXPRESSION_LEVEL | CONFIDENCE_SCORING | GLOBAL_SCORING | PUBMED_ID |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Gefitinib | SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 0.684 | 31233201 |
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | NA | ALDEFLUOR assay and FACs followed by SFA and RT-PCR | NA | 0.48 | 0.684 | 22935675 |
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.684 | 33955683 |
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Osimertinib | SFA followed by Western Blotting | NA | 0.48 | 0.684 | 30910592 |
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Osimertinib+Gefitinib | SFA followed by Western Blotting | NA | 0.48 | 0.684 | 30910592 |
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Afatinib | ALDEFLUOR assay followed by FACs | NA | 0.48 | 0.684 | 28521301 |
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | NA | ALDEFLUOR assay followed by FACs and SFA | NA | 0.48 | 0.684 | 28927099 |
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Erlotinib | FACs followed by ALDEFLUOR assay and SFA | NA | 0.48 | 0.684 | 24047698 |
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Gefitinib | qRT-PCR | NA | 0.48 | 0.684 | 33764690 |
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Gefitinib | qPCR followed by SFA and Tumorigenicity assay | NA | 0.48 | 0.684 | 24489728 |
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Gefitinib | ALDEFLUOR assay and SFA | NA | 0.48 | 0.684 | 31765940 |
| ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Gefitinib | ALDEFLUOR assay followed by SP assay and Tumorigenicity assay | NA | 0.48 | 0.684 | 25871388 |
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Gefitinib | SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 1 | 31233201 |
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Gefitinib | Western Blotting followed by SFA | NA | 0.48 | 1 | 29285189 |
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Cisplatin | SFA followed by IF staining | NA | 0.48 | 1 | 31966561 |
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Cisplatin | SFA followed by IF staining | NA | 0.48 | 1 | 31966561 |
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Gefitinib | qRT-PCR | NA | 0.48 | 1 | 30480362 |
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Osimertinib | SFA followed by FACs | NA | 0.48 | 1 | 30910592 |
| CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Osimertinib+Gefitinib | SFA followed by FACs | NA | 0.48 | 1 | 30910592 |
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Gefitinib | SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 0.6448 | 31233201 |
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Gefitinib | qRT-PCR and IF staining | NA | 0.48 | 0.6448 | 33764690 |
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Cisplatin | SFA followed by IF staining and qRT-PCR | NA | 0.48 | 0.6448 | 31966561 |
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | NA | CFA and SFA followed by IF staining and RT-PCR | NA | 0.48 | 0.6448 | 25960639 |
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Cisplatin | SFA followed by IF staining and qPCR | NA | 0.48 | 0.6448 | 31966561 |
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Erlotinib | FACs followed by qRT-PCR | NA | 0.48 | 0.6448 | 28901474 |
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.6448 | 33955683 |
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | NA | Culture on polycaprolactone electrospun (PCL-ES) scaffolds and SFA followed by qRT-PCR | NA | 0.48 | 0.6448 | 34771484 |
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Gefitinib | Culture on polycaprolactone electrospun (PCL-ES) scaffolds and SFA followed by qRT-PCR | NA | 0.48 | 0.6448 | 34771484 |
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Gefitinib | qPCR followed by SFA and Tumorigenicity assay | NA | 0.48 | 0.6448 | 24489728 |
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Gefitinib | qRT-PCR | NA | 0.48 | 0.6448 | 30480362 |
| POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Gefitinib | SP assay followed by RT-PCR and Tumorigenicity assay | NA | 0.48 | 0.6448 | 25871388 |
| CTNNB1 | 2514 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Cisplatin | SFA followed by IF staining and qRT-PCR | NA | 0.44 | 0.0647 | 31966561 |
| CTNNB1 | 2514 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Cisplatin | SFA followed by IF staining and qPCR | NA | 0.44 | 0.0647 | 31966561 |
| KLF4 | 6348 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | NA | CFA and SFA followed by IF staining and RT-PCR | NA | 0.44 | 0.0891 | 25960639 |
| KLF4 | 6348 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | NA | FACs followed by SFA and RT-PCR | NA | 0.44 | 0.0891 | 22935675 |
| KLF4 | 6348 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Cisplatin | SFA followed by qRT-PCR | NA | 0.44 | 0.0891 | 31966561 |
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | NA | CFA and SFA followed by IF staining and RT-PCR | NA | 0.44 | 0.5461 | 25960639 |
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | NA | FACs followed by SFA and RT-PCR | NA | 0.44 | 0.5461 | 22935675 |
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | NA | Culture on polycaprolactone electrospun (PCL-ES) scaffolds and SFA followed by qRT-PCR | NA | 0.44 | 0.5461 | 34771484 |
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Gefitinib | Culture on polycaprolactone electrospun (PCL-ES) scaffolds and SFA followed by qRT-PCR | NA | 0.44 | 0.5461 | 34771484 |
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Gefitinib | qRT-PCR | NA | 0.44 | 0.5461 | 33764690 |
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Cisplatin | SFA followed by qRT-PCR | NA | 0.44 | 0.5461 | 31966561 |
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Gefitinib | qPCR followed by SFA and Tumorigenicity assay | NA | 0.44 | 0.5461 | 24489728 |
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Gefitinib | qRT-PCR | NA | 0.44 | 0.5461 | 30480362 |
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Cisplatin | SFA followed by qPCR | NA | 0.44 | 0.5461 | 31966561 |
| NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Gefitinib | SP assay followed by RT-PCR and Tumorigenicity assay | NA | 0.44 | 0.5461 | 25871388 |
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Gefitinib | qRT-PCR and IF staining | NA | 0.44 | 0.7582 | 33764690 |
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Gefitinib | FACs followed by Western Blotting | NA | 0.44 | 0.7582 | 27690301 |
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Erlotinib | FACs followed by qRT-PCR | NA | 0.44 | 0.7582 | 28901474 |
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | NA | SFA followed by Western Blotting | NA | 0.44 | 0.7582 | 33955683 |
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Gefitinib | Western Blotting followed by SFA | NA | 0.44 | 0.7582 | 29285189 |
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Cisplatin | SFA followed by IF staining | NA | 0.44 | 0.7582 | 31966561 |
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Cisplatin | SFA followed by IF staining | NA | 0.44 | 0.7582 | 31966561 |
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Gefitinib | qPCR followed by SFA and Tumorigenicity assay | NA | 0.44 | 0.7582 | 24489728 |
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Gefitinib | qRT-PCR | NA | 0.44 | 0.7582 | 30480362 |
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | NA | FACs and CFA | NA | 0.44 | 0.7582 | 32329414 |
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Osimertinib | SFA followed by FACs | NA | 0.44 | 0.7582 | 30910592 |
| PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Osimertinib+Gefitinib | SFA followed by FACs | NA | 0.44 | 0.7582 | 30910592 |
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Cisplatin | SFA followed by IF staining and qRT-PCR | NA | 0.44 | 0.5695 | 31966561 |
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | NA | CFA and SFA followed by IF staining and RT-PCR | NA | 0.44 | 0.5695 | 25960639 |
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Cisplatin | SFA followed by IF staining and qPCR | NA | 0.44 | 0.5695 | 31966561 |
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Erlotinib | FACs followed by qRT-PCR | NA | 0.44 | 0.5695 | 28901474 |
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | NA | FACs followed by SFA and RT-PCR | NA | 0.44 | 0.5695 | 22935675 |
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | NA | SFA followed by Western Blotting | NA | 0.44 | 0.5695 | 33955683 |
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Osimertinib | SFA followed by Western Blotting | NA | 0.44 | 0.5695 | 30910592 |
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Osimertinib+Gefitinib | SFA followed by Western Blotting | NA | 0.44 | 0.5695 | 30910592 |
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | NA | Culture on polycaprolactone electrospun (PCL-ES) scaffolds and SFA followed by qRT-PCR | NA | 0.44 | 0.5695 | 34771484 |
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Gefitinib | Culture on polycaprolactone electrospun (PCL-ES) scaffolds and SFA followed by qRT-PCR | NA | 0.44 | 0.5695 | 34771484 |
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Gefitinib | qPCR followed by SFA and Tumorigenicity assay | NA | 0.44 | 0.5695 | 24489728 |
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Gefitinib | qRT-PCR | NA | 0.44 | 0.5695 | 30480362 |
| SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Gefitinib | SP assay followed by RT-PCR and Tumorigenicity assay | NA | 0.44 | 0.5695 | 25871388 |
| BMI1 | 1066 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | NA | FACs followed by SFA and RT-PCR | NA | 0.32 | 0.1135 | 22935675 |
| BMI1 | 1066 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Gefitinib | qRT-PCR | NA | 0.32 | 0.1135 | 33764690 |
| CACNA2D1 | 1399 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | NA | FACs followed by qPCR and SFA | NA | 0.32 | 0.0064 | 30464601 |
| NES | 7756 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | NA | FACs followed by SFA and RT-PCR | NA | 0.32 | 0.0573 | 22935675 |
| ABCB1 | 40 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | NA | Culture on polycaprolactone electrospun (PCL-ES) scaffolds and SFA followed by qRT-PCR | NA | 0.2 | 0.0604 | 34771484 |
| ABCB1 | 40 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Gefitinib | Culture on polycaprolactone electrospun (PCL-ES) scaffolds and SFA followed by qRT-PCR | NA | 0.2 | 0.0604 | 34771484 |
| ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | NA | Culture on polycaprolactone electrospun (PCL-ES) scaffolds and SFA followed by qRT-PCR | NA | 0.2 | 0.1739 | 34771484 |
| ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Gefitinib | Culture on polycaprolactone electrospun (PCL-ES) scaffolds and SFA followed by qRT-PCR | NA | 0.2 | 0.1739 | 34771484 |
| CD24 | 1645 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Gefitinib | qRT-PCR | NA | 0.2 | 0.456 | 30480362 |
| CXCR4 | 2561 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Gefitinib | qRT-PCR | NA | 0.2 | 0.0498 | 33764690 |
| CXCR4 | 2561 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Gefitinib | qPCR followed by SFA and Tumorigenicity assay | NA | 0.2 | 0.0498 | 24489728 |
| CXCR4 | 2561 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | NA | FACs and CFA | NA | 0.2 | 0.0498 | 32329414 |
| FZD1 | 4038 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Cisplatin | SFA followed by qRT-PCR | NA | 0.2 | 0.0042 | 31966561 |
| FZD1 | 4038 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Cisplatin | SFA followed by qPCR | NA | 0.2 | 0.0042 | 31966561 |
| FZD10 | 4039 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Cisplatin | SFA followed by qRT-PCR | NA | 0.2 | 0.0021 | 31966561 |
| FZD10 | 4039 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Cisplatin | SFA followed by qPCR | NA | 0.2 | 0.0021 | 31966561 |
| KLF5 | 6349 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Cisplatin | SFA followed by qPCR | NA | 0.2 | 0.0042 | 31966561 |
| LRP5 | 6697 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Cisplatin | SFA followed by qRT-PCR | NA | 0.2 | 0.0042 | 31966561 |
| LRP5 | 6697 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Cisplatin | SFA followed by qPCR | NA | 0.2 | 0.0042 | 31966561 |
| MIR127 | 31509 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | NA | SFA followed by qPCR and Tumorigenicity assay | NA | 0.2 | 0.0042 | 27869168 |
| MYC | 7553 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Cisplatin | SFA followed by qRT-PCR | NA | 0.2 | 0.1304 | 31966561 |
| MYC | 7553 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Cisplatin | SFA followed by qPCR | NA | 0.2 | 0.1304 | 31966561 |
| MYC | 7553 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Gefitinib | SFA followed by RT-PCR | NA | 0.2 | 0.1304 | 31233201 |
| WNT7B | 12787 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Cisplatin | SFA followed by qRT-PCR | NA | 0.2 | 0.0042 | 31966561 |
| WNT7B | 12787 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Cisplatin | SFA followed by qPCR | NA | 0.2 | 0.0042 | 31966561 |
| ZEB1 | 11642 | LTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | Gefitinib | qRT-PCR | NA | 0.2 | 0.0074 | 33764690 |
| AXIN2 | 904 | HTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | NA | FACs for CSCs marker and SFA followed by Transcriptomics | Up | 0.04 | 0.0064 | 28927099 |
| CDKN1A | 1784 | HTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | NA | FACs for CSCs marker and SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 28927099 |
| COL11A2 | 2187 | HTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | NA | FACs for CSCs marker and SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 28927099 |
| COL1A2 | 2198 | HTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | NA | FACs for CSCs marker and SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 28927099 |
| COL4A1 | 2202 | HTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | NA | FACs for CSCs marker and SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 28927099 |
| FGF22 | 3679 | HTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | NA | FACs for CSCs marker and SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 28927099 |
| FLT3LG | 3766 | HTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | NA | FACs for CSCs marker and SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 28927099 |
| GNG13 | 14131 | HTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | NA | FACs for CSCs marker and SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 28927099 |
| GNG2 | 4404 | HTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | NA | FACs for CSCs marker and SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 28927099 |
| GNGT1 | 4411 | HTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | NA | FACs for CSCs marker and SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 28927099 |
| IL6 | 6018 | HTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | NA | FACs for CSCs marker and SFA followed by Transcriptomics | Up | 0.04 | 0.0191 | 28927099 |
| MMP28 | 14366 | HTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | NA | FACs for CSCs marker and SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 28927099 |
| MMP9 | 7176 | HTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | NA | FACs for CSCs marker and SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 28927099 |
| PTGS2 | 9605 | HTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | NA | FACs for CSCs marker and SFA followed by Transcriptomics | Up | 0.04 | 0.0064 | 28927099 |
| WNT10B | 12775 | HTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | NA | FACs for CSCs marker and SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 28927099 |
| WNT11 | 12776 | HTM | Non Small Cell Lung Cancer | Adenocarcinoma | PC9 | NA | FACs for CSCs marker and SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 28927099 |